April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Assessment of Genetic Risk at CC3 and Mitochondrial DNA Polymorphism A4917G After Adjustment for CFH, ARMS2, CFB and Smoking in an Irish AMD Cohort
Author Affiliations & Notes
  • G. J. McKay
    Ophthalmology,
    Queen's University Belfast, Belfast, United Kingdom
  • S. Dasari
    Ophthalmology,
    Queen's University Belfast, Belfast, United Kingdom
  • U. Chakravarthy
    Ophthalmology,
    Queen's University Belfast, Belfast, United Kingdom
  • A. E. Hughes
    Medical Genetics,
    Queen's University Belfast, Belfast, United Kingdom
  • G. Silvestri
    Ophthalmology,
    Queen's University Belfast, Belfast, United Kingdom
  • Footnotes
    Commercial Relationships  G.J. McKay, None; S. Dasari, None; U. Chakravarthy, None; A.E. Hughes, None; G. Silvestri, None.
  • Footnotes
    Support  The Guide Dogs for the Blind Association UK (2005-01a); Research and Development Office, Northern Ireland Health Personal Social Services (RRG 4.5).
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 1602. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      G. J. McKay, S. Dasari, U. Chakravarthy, A. E. Hughes, G. Silvestri; Assessment of Genetic Risk at CC3 and Mitochondrial DNA Polymorphism A4917G After Adjustment for CFH, ARMS2, CFB and Smoking in an Irish AMD Cohort. Invest. Ophthalmol. Vis. Sci. 2009;50(13):1602.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Polymorphic variation within complement component 3 and the mitochondrial SNP A4917G have been reported to be associated with AMD. We assess the impact of these variants within an Irish AMD sample after adjusting for other known risk factors.

Methods: : Patient samples with documented end-stage neovascular AMD (n=511) and an age and sex-matched controls (n=446) underwent full ophthalmic examination and participated in a short questionnaire to detail history of smoking, micro and macro angiopathic disease, drug history, refractive status, eye colour, body mass index and family history. Genotype analysis was undertaken for the CC3 SNP rs2230199 and the mitochondrial SNP A4917G. Genotyping was performed by SNaPshot (ABI). Data was combined with that reported previously for CFH, ARMS2, CFB and smoking1.

Results: : CC3 SNP rs2230199 was significantly associated with AMD with increased Odds Ratio (OR) of 1.49 (P<0.001; Confidence Intervals (CI): 1.21-1.83) in a univariate analysis. Inclusion of risk data for CFH, ARMS2, CFB and smoking within logistic regression increased the OR to 1.57 (P<0.001; CI: 1.20-2.05). Univariate analysis of the mitochondrial SNP A4917G showed marginal significance (P=0.04; OR=1.26; CI: 1.01-1.58) which was no longer significant when other covariates were assessed within the model.

Conclusions: : Our results show the effect exerted by CC3 is similar in magnitude to that of CFB. Indeed both variants have similar minor allele frequencies and population attributable risk (PAR). Both ARMS2 and CFH exert an effect of greater magnitude and are at a higher frequency in the population and as such, are likely to have a higher PAR. While the mitochondrial SNP A4917G was marginally significant when assessed alone, it failed to do so in a multivariate analysis. Previous reports identified the need to adjust for age when measuring the effect of this SNP2 which is ongoing in this sample. Evidence suggests increased mitochondrial germline mutation accumulation with time, particularly in males and certain mitochondrial haplogroups have been implicated in other age-related disorders. As such, the effect of age or sex bias will be assessed.1. McKay et al. Invest Ophthalmol Vis Sci 2008; (eprint ahead of publication).2. Canter et al. PLoS Genet 2008; 3 (e2091).

Keywords: age-related macular degeneration • genetics • clinical (human) or epidemiologic studies: risk factor assessment 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×